HF in≥65 years?
Patients with ‘red flags’, such as HF in≥65 years and an increased left ventricular wall thickness, should be screened for cardiac amyloidosis. Tafamidis is recommended in patients who have New York Heart Association class I or II symptoms and transthyretin-cardiac amyloidosis to reduce symptoms, cardiovascular hospitalization, and mortality.
有“警示征”的患者,如年龄≥65岁发生心力衰竭且左心室壁厚度增加,应筛查心脏淀粉样变性。推荐纽约心脏协会I级或II级症状和甲状腺素运载蛋白-心脏淀粉样变性患者使用氯苯唑酸,以减少症状、心血管住院和死亡率。
HF in≥65 years指“年龄≥65岁发生心力衰竭”还是“心力衰竭已≥65年”?谢谢
最后编辑于 2022-10-09 · 浏览 755